E Amir
Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials
AlHashem H, Al-Mubarak M, Vera-Badillo F, Templeton A, Ocana A, Šeruga B, Amir E. Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. Clin Oncol (R Coll Radiol) 2015
Nov 2, 2015Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials
Nov 2, 2015Clin Oncol (R Coll Radiol) 2015
AlHashem H Y, Al-Mubarak M, Vera-Badillo F E, Templeton Arnoud, Ocana A, Šeruga B, Amir E
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†
van Soest R, Tannock I, Eisenberger M, Rosenthal M, Tombal B, Amir E, Sonpavde G, Mercier F, Vera-Badillo F, Templeton A, De Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†. Ann Oncol 2014
Dec 15, 2014Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†
Dec 15, 2014Ann Oncol 2014
van Soest R J, Tannock I F, Eisenberger M A, Rosenthal M, Tombal B, Amir E, Sonpavde G, Mercier F, Vera-Badillo F E, Templeton Arnoud, De Wit R
Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer
McNamara M, Templeton A, Maganti M, Walter T, Horgan A, McKeever L, Min T, Amir E, Knox J. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer 2014; 50:1581-9.
Mar 11, 2014Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer
Mar 11, 2014Eur J Cancer 2014; 50:1581-9
McNamara M G, Templeton Arnoud, Maganti M, Walter T, Horgan A M, McKeever L, Min T, Amir E, Knox J J
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials
Templeton A, Amir E, Pond G, Joshua A, Sridhar S, Moore M, Knox J, Leibowitz-Amit R, De Gouveia P, Attalla M, Wang L, Vera-Badillo F, Tannock I. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24:2972-7.
Oct 14, 2013Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials
Oct 14, 2013Ann Oncol 2013; 24:2972-7
Templeton Arnoud, Amir E, Pond G R, Joshua A M, Sridhar S S, Moore M, Knox J J, Leibowitz-Amit R, De Gouveia P, Attalla M, Wang L, Vera-Badillo F E, Tannock I F